<p>Insmed（纳斯达克股票代码：INSM - 获取免费报告）在周四向投资者发布的报告中，TD Cowen 将其目标股价从 269.00 美元下调至 241.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。TD Cowen 的目标价意味着该股票相较于之前的收盘价有 44.51% 的潜在上涨空间。</p>
<ul>
<li>罗素再平衡：3 只股票准备上涨</li>
</ul>
<p>其他一些券商也最近对 INSM 发表了评论。Redburn Partners 在 12 月 4 日的报告中将 Insmed 的目标价格设定为 263.00 美元。摩根士丹利将 Insmed 的目标价从 126.00 美元上调至 144.00 美元，并在 8 月 21 日的研究报告中给予该公司 “等权重” 评级。瑞穗证券在周四的研究报告中将 Insmed 的目标价格设定为 212.00 美元。Rothschild &amp; Co Redburn 在 12 月 4 日的研究报告中开始覆盖 Insmed 的股票。他们给予该公司 “买入” 评级，并设定 263.00 美元的目标价。最后，Evercore ISI 在 10 月 1 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Insmed 的目标价设定为 180.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，21 位分析师给予 “买入” 评级，1 位分析师给予 “持有” 评级，1 位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Insmed 的平均评级为 “适度买入”，共识目标价为 202.55 美元。</p>
<p><strong>查看我们最新的 INSM 股票分析</strong></p>
<h2>Insmed 股票下跌 16.0%</h2>
<ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
<p>周四中午交易时，纳斯达克 INSM 的股票下跌 31.69 美元，跌至 166.77 美元。该股票交易量为 6,858,296 股，而其平均交易量为 2,694,783 股。Insmed 的 52 周低点为 60.40 美元，52 周高点为 212.75 美元。该股票的 50 日移动平均价格为 187.37 美元，200 日移动平均价格为 142.14 美元。该公司的市值为 355.7 亿美元，市盈率为-26.87，贝塔系数为 1.01。该公司的债务与股本比率为 0.59，速动比率为 4.34，流动比率为 4.63。</p>
<p>Insmed（纳斯达克股票代码：INSM - 获取免费报告）最近于 10 月 30 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为-1.75 美元，低于市场共识预期的-1.35 美元，差距为 0.40 美元。Insmed 的股本回报率为-183.55%，净利润率为-264.83%。该公司本季度的收入为 1.4234 亿美元，而分析师预期为 1.1433 亿美元。在去年同期，该公司每股收益为-1.27 美元。与去年同期相比，该公司的收入增长了 52.4%。研究分析师预计 Insmed 今年的每股收益将为-4.56 美元。</p>
<h2>Insmed 的内部交易</h2>
<p>在其他 Insmed 的新闻中，内部人士 Michael Alexander Smith 在 11 月 3 日的交易中出售了 27,130 股该股票。股票以平均 183.78 美元的价格出售，总价值为 4,985,951.40 美元。交易后，该内部人士直接持有 54,902 股公司股票，价值为 10,089,889.56 美元。这代表其持股比例减少了 33.07%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，内部人士 Orlov S. Nicole Schaeffer 在 11 月 12 日的交易中出售了 30,000 股公司的股票。股票以平均 194.00 美元的价格出售，总价值为 5,820,000.00 美元。交易后，该内部人士直接持有 36,461 股公司股票，价值为 7,073,434 美元。这代表其持股比例减少了 45.14%。该出售的披露信息可在 SEC 的文件中找到。过去三个月，内部人士共出售了 147,130 股公司股票，价值为 28,480,051 美元。目前，内部人士持有该股票的比例为 3.00%。</p>
<h2>对 Insmed 的对冲基金看法</h2>
<p>机构投资者最近对该公司的持仓进行了调整。CIBC 私人财富集团在第三季度将其在 Insmed 的持股增加了 42.1%。CIBC 私人财富集团目前持有 179 股生物制药公司的股票，价值为 26,000 美元，此前在上个季度又购买了 53 股。Stone House 投资管理公司在第三季度购买了 Insmed 的新头寸，价值约为 29,000 美元。SBI 证券有限公司在第三季度将其在 Insmed 的持股增加了 404.9%。SBI 证券有限公司目前持有 207 股生物制药公司的股票，价值为 30,000 美元，此前在上个季度又购买了 166 股。MassMutual 私人财富与信托公司在第三季度将其在 Insmed 的持股增加了 59.6%。MassMutual 私人财富与信托公司目前持有 217 股生物制药公司的股票，价值为 31,000 美元，此前在上个季度又购买了 81 股。最后，Whittier Trust Co. of Nevada Inc.在第三季度将其在 Insmed 的持股增加了 169.7%。Whittier Trust Co. of Nevada Inc.目前持有 240 股生物制药公司的股票，价值为 38,000 美元，此前在上个季度又购买了 151 股。</p>
<h2>关于 Insmed</h2>
<p>（获取免费报告）</p>
<p>Insmed 公司是一家全球生物制药公司，致力于改变严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），该产品已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或无替代治疗方案的抗菌药物组合的一部分。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票而非 Insmed</li>
<li>如何计算股票利润</li>
<li>Dollar General 的转机可能会在 2026 年推动股票上涨</li>
<li>如何购买黄金股票并投资黄金</li>
<li>不要对 AppLovin 下赌注：反对空头的理由</li>
<li>什么是股息之王？</li>
<li>美光第一季度业绩表明 “人工智能泡沫远未破裂”</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
<p>在考虑 Insmed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
<p>虽然 Insmed 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INSM

<p>TD Cowen 将 Insmed 的目标股价从 269.00 美元下调至 241.00 美元，维持 “买入” 评级。Insmed 的股价下跌 16%，至 166.77 美元，较新目标价有 44.51% 的上涨潜力。Insmed 报告季度每股亏损 1.75 美元，未能达到预期。内部人士出售了股份，减少了他们的持股比例。机构投资者调整了在该公司的持仓</p>

<p>Insmed (NASDAQ:INSM - Get Free Report) had its price target reduced by investment analysts at TD Cowen from $269.00 to $241.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. TD Cowen's price objective points to a potential upside of 44.51% from the stock's previous close.</p>
<div class="lb-trans"><p>Insmed（纳斯达克股票代码：INSM - 获取免费报告）在周四向投资者发布的报告中，TD Cowen 将其目标股价从 269.00 美元下调至 241.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。TD Cowen 的目标价意味着该股票相较于之前的收盘价有 44.51% 的潜在上涨空间。</p>
</div><ul>
<li>Russell Rebalance: 3 Stocks Ready to Move Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>罗素再平衡：3 只股票准备上涨</li>
</ul>
</div><p>A number of other brokerages have also recently commented on INSM. Redburn Partners set a $263.00 target price on Insmed in a report on Thursday, December 4th. Morgan Stanley upped their price objective on shares of Insmed from $126.00 to $144.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, August 21st. Mizuho set a $212.00 target price on shares of Insmed in a research note on Thursday. Rothschild &amp; Co Redburn began coverage on shares of Insmed in a research note on Thursday, December 4th. They issued a &#34;buy&#34; rating and a $263.00 price target for the company. Finally, Evercore ISI reaffirmed an &#34;outperform&#34; rating and set a $180.00 price target on shares of Insmed in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Insmed has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $202.55.</p>
<div class="lb-trans"><p>其他一些券商也最近对 INSM 发表了评论。Redburn Partners 在 12 月 4 日的报告中将 Insmed 的目标价格设定为 263.00 美元。摩根士丹利将 Insmed 的目标价从 126.00 美元上调至 144.00 美元，并在 8 月 21 日的研究报告中给予该公司 “等权重” 评级。瑞穗证券在周四的研究报告中将 Insmed 的目标价格设定为 212.00 美元。Rothschild &amp; Co Redburn 在 12 月 4 日的研究报告中开始覆盖 Insmed 的股票。他们给予该公司 “买入” 评级，并设定 263.00 美元的目标价。最后，Evercore ISI 在 10 月 1 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Insmed 的目标价设定为 180.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，21 位分析师给予 “买入” 评级，1 位分析师给予 “持有” 评级，1 位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Insmed 的平均评级为 “适度买入”，共识目标价为 202.55 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on INSM</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 INSM 股票分析</strong></p>
</div><h2>Insmed Stock Down 16.0%</h2>
<div class="lb-trans"><h2>Insmed 股票下跌 16.0%</h2>
</div><ul>
<li>Stock Rotation is Underway: Here are the Winners Moving Forward</li>
</ul>
<div class="lb-trans"><ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
</div><p>Shares of NASDAQ INSM traded down $31.69 during mid-day trading on Thursday, hitting $166.77. 6,858,296 shares of the stock traded hands, compared to its average volume of 2,694,783. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75. The stock has a fifty day moving average price of $187.37 and a 200-day moving average price of $142.14. The company has a market cap of $35.57 billion, a price-to-earnings ratio of -26.87 and a beta of 1.01. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.</p>
<div class="lb-trans"><p>周四中午交易时，纳斯达克 INSM 的股票下跌 31.69 美元，跌至 166.77 美元。该股票交易量为 6,858,296 股，而其平均交易量为 2,694,783 股。Insmed 的 52 周低点为 60.40 美元，52 周高点为 212.75 美元。该股票的 50 日移动平均价格为 187.37 美元，200 日移动平均价格为 142.14 美元。该公司的市值为 355.7 亿美元，市盈率为-26.87，贝塔系数为 1.01。该公司的债务与股本比率为 0.59，速动比率为 4.34，流动比率为 4.63。</p>
</div><p>Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm had revenue of $142.34 million during the quarter, compared to analysts' expectations of $114.33 million. During the same period in the prior year, the company posted ($1.27) earnings per share. The company's revenue was up 52.4% compared to the same quarter last year. Research analysts anticipate that Insmed will post -4.56 EPS for the current year.</p>
<div class="lb-trans"><p>Insmed（纳斯达克股票代码：INSM - 获取免费报告）最近于 10 月 30 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为-1.75 美元，低于市场共识预期的-1.35 美元，差距为 0.40 美元。Insmed 的股本回报率为-183.55%，净利润率为-264.83%。该公司本季度的收入为 1.4234 亿美元，而分析师预期为 1.1433 亿美元。在去年同期，该公司每股收益为-1.27 美元。与去年同期相比，该公司的收入增长了 52.4%。研究分析师预计 Insmed 今年的每股收益将为-4.56 美元。</p>
</div><h2>Insider Transactions at Insmed</h2>
<div class="lb-trans"><h2>Insmed 的内部交易</h2>
</div><p>In other Insmed news, insider Michael Alexander Smith sold 27,130 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the transaction, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. This represents a 33.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the company's stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total value of $5,820,000.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at $7,073,434. This represents a 45.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 147,130 shares of company stock valued at $28,480,051 over the last three months. 3.00% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Insmed 的新闻中，内部人士 Michael Alexander Smith 在 11 月 3 日的交易中出售了 27,130 股该股票。股票以平均 183.78 美元的价格出售，总价值为 4,985,951.40 美元。交易后，该内部人士直接持有 54,902 股公司股票，价值为 10,089,889.56 美元。这代表其持股比例减少了 33.07%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，内部人士 Orlov S. Nicole Schaeffer 在 11 月 12 日的交易中出售了 30,000 股公司的股票。股票以平均 194.00 美元的价格出售，总价值为 5,820,000.00 美元。交易后，该内部人士直接持有 36,461 股公司股票，价值为 7,073,434 美元。这代表其持股比例减少了 45.14%。该出售的披露信息可在 SEC 的文件中找到。过去三个月，内部人士共出售了 147,130 股公司股票，价值为 28,480,051 美元。目前，内部人士持有该股票的比例为 3.00%。</p>
</div><h2>Hedge Funds Weigh In On Insmed</h2>
<div class="lb-trans"><h2>对 Insmed 的对冲基金看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 53 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Insmed during the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. grew its stake in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 166 shares during the last quarter. MassMutual Private Wealth &amp; Trust FSB raised its holdings in shares of Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth &amp; Trust FSB now owns 217 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 81 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 151 shares during the last quarter.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。CIBC 私人财富集团在第三季度将其在 Insmed 的持股增加了 42.1%。CIBC 私人财富集团目前持有 179 股生物制药公司的股票，价值为 26,000 美元，此前在上个季度又购买了 53 股。Stone House 投资管理公司在第三季度购买了 Insmed 的新头寸，价值约为 29,000 美元。SBI 证券有限公司在第三季度将其在 Insmed 的持股增加了 404.9%。SBI 证券有限公司目前持有 207 股生物制药公司的股票，价值为 30,000 美元，此前在上个季度又购买了 166 股。MassMutual 私人财富与信托公司在第三季度将其在 Insmed 的持股增加了 59.6%。MassMutual 私人财富与信托公司目前持有 217 股生物制药公司的股票，价值为 31,000 美元，此前在上个季度又购买了 81 股。最后，Whittier Trust Co. of Nevada Inc.在第三季度将其在 Insmed 的持股增加了 169.7%。Whittier Trust Co. of Nevada Inc.目前持有 240 股生物制药公司的股票，价值为 38,000 美元，此前在上个季度又购买了 151 股。</p>
</div><h2>About Insmed</h2>
<div class="lb-trans"><h2>关于 Insmed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.</p>
<div class="lb-trans"><p>Insmed 公司是一家全球生物制药公司，致力于改变严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），该产品已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或无替代治疗方案的抗菌药物组合的一部分。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Insmed</li>
<li>How to Calculate Stock Profit</li>
<li>Dollar General's Turnaround Could Send the Stock Higher in 2026</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>Don’t Bet Against AppLovin: The Case Against the Shorts</li>
<li>What is a Dividend King?</li>
<li>Micron’s Q1 Results Say “AI Bubble Is Far From Bursting”</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Insmed</li>
<li>如何计算股票利润</li>
<li>Dollar General 的转机可能会在 2026 年推动股票上涨</li>
<li>如何购买黄金股票并投资黄金</li>
<li>不要对 AppLovin 下赌注：反对空头的理由</li>
<li>什么是股息之王？</li>
<li>美光第一季度业绩表明 “人工智能泡沫远未破裂”</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=INSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Insmed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
</div><p>Before you consider Insmed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insmed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
</div><p>While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insmed 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insmed（NASDAQ:INSM）被 TD Cowen 给予新的 241.00 美元目标价